Physician profile
Stephen A Arrigo
NPI 1467496877
$1,347.18
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $811 · 2020: $108 · 2021: $65.59 · 2022: $114 · 2023: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $249.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $152.69 | 2019 | |
| Puma Biotechnology, INC. | $143.46 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $135.31 | 2019-2023 | |
| Progenics Pharmaceuticals, INC. | $122.28 | 2023 | Pylarify |
| Astrazeneca Pharmaceuticals LP | $110.75 | 2019 | |
| Boston Scientific Corporation | $104.98 | 2019-2023 | Spaceoar Vue System - 10ml |
| Celgene Corporation | $78.83 | 2019-2020 | |
| Eisai INC. | $70.51 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $49.38 | 2022 | |
| Telix Pharmaceuticals | $43.35 | 2023 | Illuccix |
| Ipsen Biopharmaceuticals, INC | $43.06 | 2019 | |
| Palette Life Sciences, INC. | $36.06 | 2023 | |
| Dendreon Pharmaceuticals LLC | $33.23 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $31.68 | 2019-2021 | |
| Accuray Incorporated | $31.38 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $27.88 | 2019-2020 | |
| Kyowa Kirin, INC. | $23.99 | 2019 | |
| Advanced Accelerator Applications | $18.10 | 2020 | |
| Fortovia Therapeutics, INC. | $18.00 | 2019 | |
| Merck Sharp & Dohme LLC | $16.78 | 2019 | |
| Myovant Sciences INC. | $15.98 | 2021 | |
| Clovis Oncology, INC. | $14.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.61 | 2020 | |
| Tesaro, INC. | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Arrigo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.